•  
  •  
  •  
  •  

2026-07-23 02:34:34

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Tanla Platforms Reports Strong Q1 FY27 Results with Net Profit Rising 20.1% YoY to ₹142 Crore
  • United Spirits Limited Reports Q1 FY27 Results with Consolidated Net Profit Rising to ₹463 Crore
  • Mahindra Lifespaces and Sumitomo Corporation strengthen partnership to expand Origins by Mahindra in Chennai
  • Waaree Renewable Technologies Delivers Strong Q1 FY27 Performance with 53.23% Revenue Surge to ₹924.25 Crore
  • Signatureglobal Homes Ltd acquires saleable area of 0.38 mn sq.ft

Keywords Selected:  StridesPharmaGlobal

Stock Report

  • Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg, Expanding the Existing OTC Portfolio
  • Strides receives USFDA approval for Fluoxetine Tabs 60 mg
  • Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg
  • Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
  • Strides receives USFDA approval for Pregabalin Capsules
  • Strides receives USFDA approval for Generic Suprep® Bowel Prep Kit
  • Strides receives USFDA approval for Levetiracetam Oral Solution
  • Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets
  • Strides receives USFDA approval for Icosapent Ethyl Capsules
  • Strides receives USFDA approval for Icosapent Ethyl Capsules
  • Strides receives tentative USFDA approval for Dolutegravir / Lamivudine / Tenofovir Disproxil Fumurate tablets
  • Strides receives tentative USFDA approval for Dolutegravir tablets
  • Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension
  • Strides Pharma Science Ltd receives deferred consideration of AUD 94 million
  • Strides receives USFDA approval for Potassium Chloride Oral Solution
  • Strides receives USFDA approval for Colchicine Tablets
  • Strides receives USFDA approval for Amantadine Hydrochloride Softgel Capsules

Latest Post

  • Tanla Platforms Reports Strong Q1 FY27 Results with Net Profit Rising 20.1% YoY to ₹142 Crore
  • United Spirits Limited Reports Q1 FY27 Results with Consolidated Net Profit Rising to ₹463 Crore
  • Mahindra Lifespaces and Sumitomo Corporation strengthen partnership to expand Origins by Mahindra in Chennai
  • Waaree Renewable Technologies Delivers Strong Q1 FY27 Performance with 53.23% Revenue Surge to ₹924.25 Crore
  • Signatureglobal Homes Ltd acquires saleable area of 0.38 mn sq.ft


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025